218 related articles for article (PubMed ID: 25116970)
1. The use of self-administered subcutaneous methotrexate for the treatment of psoriasis.
Chiaravalloti AJ; Strober BE
J Drugs Dermatol; 2014 Aug; 13(8):929-31. PubMed ID: 25116970
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: a comparative study.
Ranjan N; Sharma NL; Shanker V; Mahajan VK; Tegta GR
J Dermatolog Treat; 2007; 18(5):295-300. PubMed ID: 17852635
[TBL] [Abstract][Full Text] [Related]
3. Adherence of self-administered subcutaneous methotrexate in patients with chronic plaque-type psoriasis.
Vidal D; Salleras M; Romaní J; Ribera M; Gallardo F; Viñas M; Xifra A; García-Navarro X; Bordas X; Ferran M; Carrascosa JM
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e131-e132. PubMed ID: 26446358
[No Abstract] [Full Text] [Related]
4. Methotrexate-betamethasone weekly oral pulse in psoriasis.
Gupta R; Gupta S
J Dermatolog Treat; 2007; 18(5):291-4. PubMed ID: 17852636
[TBL] [Abstract][Full Text] [Related]
5. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.
Yamauchi PS; Lowe NJ
Int J Dermatol; 2008 Feb; 47(2):202-4. PubMed ID: 18211500
[TBL] [Abstract][Full Text] [Related]
6. [Subcutaneous methotrexate in psoriasis and psoriatic arthritis treatment].
Szczerkowska-Dobosz A
Wiad Lek; 2016; 69(4):675-679. PubMed ID: 27941209
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis.
Yesudian PD; Leman J; Balasubramaniam P; Macfarlane AW; Al-Niaimi F; Griffiths CE; Burden AD; Warren RB
J Drugs Dermatol; 2016 Mar; 15(3):345-9. PubMed ID: 26954320
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis: the new and the old.
Feldman SR
J Drugs Dermatol; 2014 Aug; 13(8):894. PubMed ID: 25116962
[No Abstract] [Full Text] [Related]
9. Pharmacokinetic profile of methotrexate in psoriatic skin via the oral or subcutaneous route using dermal microdialysis showing higher methotrexate bioavailability in psoriasis plaques than in non-lesional skin.
Quist SR; Quist J; Birkenmaier J; Stauch T; Gollnick HP
J Eur Acad Dermatol Venereol; 2016 Sep; 30(9):1537-43. PubMed ID: 27005005
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis: a single-centre prospective study.
Woolf RT; West SL; Arenas-Hernandez M; Hare N; Peters van Ton AM; Lewis CM; Marinaki AM; Barker JN; Smith CH
Br J Dermatol; 2012 Jul; 167(1):165-73. PubMed ID: 22309614
[TBL] [Abstract][Full Text] [Related]
11. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study.
Gisondi P; Giglio MD; Girolomoni G
J Dermatolog Treat; 2006; 17(3):172-5. PubMed ID: 16854760
[TBL] [Abstract][Full Text] [Related]
12. The METOP Study: Further Evidence for the Use of Subcutaneous Methotrexate in Psoriasis.
Morgado-Carrasco D; Fustà-Novell X; Riera Monroig J; Mascaró Galy JM
Actas Dermosifiliogr; 2017 Nov; 108(9):865-866. PubMed ID: 28583269
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
Dogra S; Krishna V; Kanwar AJ
Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
[TBL] [Abstract][Full Text] [Related]
14. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
15. [Methotrexate in psoriasis: do we need to give a test dose?].
Carretero-Hernández G
Actas Dermosifiliogr; 2012; 103(1):1-4. PubMed ID: 22093543
[No Abstract] [Full Text] [Related]
16. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.
Reich K; Langley RG; Papp KA; Ortonne JP; Unnebrink K; Kaul M; Valdes JM
N Engl J Med; 2011 Oct; 365(17):1586-96. PubMed ID: 22029980
[TBL] [Abstract][Full Text] [Related]
17. The treatment of psoriasis vulgaris: 1% topical methotrexate gel.
Eskicirak B; Zemheri E; Cerkezoglu A
Int J Dermatol; 2006 Aug; 45(8):965-9. PubMed ID: 16911386
[TBL] [Abstract][Full Text] [Related]
18. Topical psoriasis therapies and unmet patient needs: the importance of optimizing methotrexate.
Greenberg R
Cutis; 2016 Jan; 97(1):55-6. PubMed ID: 26919356
[No Abstract] [Full Text] [Related]
19. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
20. Considerable variation among Iranian dermatologists in the dosing and monitoring of methotrexate for treating psoriasis.
Zargari O; Hejazi S; Shahidi-Dadras M; Younespour S; Robati R; Firooz A; Toosi P; Feldman SR
Int J Dermatol; 2014 Mar; 53(3):385-9. PubMed ID: 24134730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
